The CenterWatch Monthly, November 2012

Thursday, November 1, 2012 08:00 AM

Keeping potential patients connected to trials

Industry efforts to address patient recruitment challenges have widely overlooked an important issue: What happens to patients who volunteer to participate in a clinical trial but do not meet the eligibility criteria? How well does the industry do in helping them find other trial opportunities? When patients volunteer for a clinical trial but are disqualified during the screening process, for any number of reasons, many are disappointed and disillusioned, and give up on participation altogether. While in the past, the industry has not addressed this issue, recent initiatives have emerged that allow companies to share more information about trials actively enrolling and redirect volunteers who don’t qualify for one study into other studies. In one groundbreaking effort…

 

Sponsors, CROs demanding more from pre-study site visits

Under increasing pressure to shorten the drug development life cycle and boost efficiency, sponsors and CROs are demanding more from the pre-study site visit. They’re now more likely than in the past to use historical data and external sources of information to evaluate site potential before the visit. Once underway, the more sophisticated—and successful—site visits probe deeply into patient recruitment ability. For those sponsors and CROs that treat it as a proforma visit, or delegate the visit to a poorly trained or uninformed CRA, it can result in a missed opportunity and waste of resources...

 

Eye on BioMarin

BioMarin’s mission statement is “making a meaningful impact in the lives of patients suffering from diseases that are often underserved and ignored,” primarily by replacing deficient enzymes in rare genetic diseases. Currently the company is marketing four products: Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), Aldurazyme (laronidase) for mucopolysaccharidosis I (MPS I), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU) and Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome. Collaborations with research scientists and universities…

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs